Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics reported a Q1 2026 net loss of $6.9 million ($0.58 per share), driven by $6.3 million in operating expenses as it advances its lead asset SER-252. The company closed a $21.2 million private placement financing, boosting its cash position to $24.5 million and extending its runway to support the ongoing Phase 1b registrational study in advanced Parkinson’s disease.
Key figures
- Revenue
- 0
- Net loss
- 6898000
- Ga expenses
- 3081000
- Rd expenses
- 3199000
- Pipe proceeds
- 21200000
- Operating expenses
- 6280000
- Weighted avg shares
- 12047000
- Cash and equivalents
- 24526000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.